Pharmacological treatment for endometriosis

Authors

DOI:

https://doi.org/10.33448/rsd-v10i7.16104

Keywords:

Pharmacological Treatment; Endometriosis; Combined therapy.

Abstract

 

Endometriosis is a gynecological disease characterized by the presence of endometrium as tissue-epithelium and stroma that develops outside the uterine cavity. It is a chronic, estrogen-dependent disease, is associated with pelvic pain, dysmenorrhea, dyspareunia and infertility. Given the great impact of this disease on the quality of life of women, there has been a growing interest in the discovery of new drugs that are more effective, tolerability and safety. For this, a literature review was carried out from articles published between 2008 and 2018 available regarding pharmacological treatments for endometriosis in the SCIENCE DIRECT and PUBMED databases. A total of 223 articles published in the last 10 years were found in "Portuguese and English". After evaluating the articles, 15 articles were selected for the present study, which complied with all the eligibility criteria proposed in the methodology. It was concluded that we can count on several types of treatments for endometriosis, but most have the objective of treating the symptoms associated with endometriosis. Currently, the specific treatment we can count on is dienogeste. In addition, there are many studies in search of new drugs and promising treatments for this pathology. Thus, more research is needed regarding the theme and that the pharmacist plays a fundamental role in the adherence to the patient's treatment.

References

Abushahin, F. (2011). Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. Fertil. Steril, v. 96, p. 939–942.

Amaral, P. P. (2017). Aspectos diagnósticos e terapêuticos da endometriose. FAEMA. Ariquemes-RO.

Anderes, K. L., et al. (2008). Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J. Pharmacol, v. 305, p. 688–695.

Brasil. Ministério da Saúde. (2002). Política Nacional de Promoção da Saúde (Documento para discussão). Secretaria de Políticas Públicas, Brasília, DF.

Chabbert-Buffet, N., et al. (2008). Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications, Hum. Reprod. v. 11, p. 293–307.

Clemenza, S., et al., (2018). From pathogenesis to clinical practice: Emerging medical treatments for endometriosis, Best Practice & Research Clinical. Obstetrics and Gynaecology.

Durón, G. R., Bolaños, M. P. (2018). Endometriosis. Costa Rica, Março.

Febrasgo – (2017). Federação Brasileira das Associações de Ginecologia e Obstetrícia - São Paulo.

Figueiredo, J., Nascimento, R. Avaliação da qualidade de vida de pacientes portadoras de endometriose após inserção do Sistema Intra-Uterino Liberador de Levonorgestrel (SIU-LNg). ACM, v. 37, p. 4, 2008.

Khazali, S. (2016). Endometriosis Classification-The Quest for the Holy Grail? J Reprod Infertil; v.17.

Kodaman, P. H. (2015). Current Strategies for Endometriosis Management. Obstetrics and Gynecology Clinics of North America, v. 42, p. 87-101.

Kumar, P., Sharma, A. (2014). Gonadotropin-releasing hormone analogs: understanding advantages and limitations, J. Hum. Reprod, v. 7, p. 170–174.

Mabrouk, M., et al. (2018). Short-term histopathological effects of dienogest therapy on ovarian endometriomas: in vivo, nonrandomized, controlled trial. Gynecol Endocrinol, v. 34(5); 399-403.

Novella-Maestre, E., et al., (2009). Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum. Reprod, v. 24, p. 1025–1035.

Pereira, A. S., et al. (2018). Metodologia da pesquisa científica. [free e-book]. Santa Maria/RS. Ed. UAB/NTE/UFSM.

Santos, D. B., et al. (2012). Uma abordagem integrada da endometriose. UFRB, Bahia.

Silva, D. M. (2017). Ensaio clínico randomizado duplo cego com resveratrol no tratamento da dor por endometriose. Universidade Federal do Rio Grande do Sul. Porto Alegre.

Tavares, N. M. C. (2018). Satisfação e padrões de sangramento das usuárias do sistema intrauterino liberador de levonorgestrel como contraceptivo e comparação com o implante contraceptivo liberador de etonogestrel em mulheres com dor pélvica associada à endometriose. 2018. 1 recurso online (98 p.). Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Campinas, SP. Disponível em: <http://www.repositorio.unicamp.br/handle/REPOSIP/331112>

Taylor, H. S., et al. (2017). Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. The New England journal of medicine, v. 377, p.28-40.

Yuan, P., et. al., (2010). Induction of a local pseudo-pregnancy for the treatment of endometriosis. Medical Hypotheses, v. 74; 56-58, China.

Zhao, Y., et al., (2015). Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis, Transl. Med, V. 7; 271.

Published

01/07/2021

How to Cite

SANTOS, C. M. do N. .; MONTE , L. E. M. do .; PINHEIRO NETO, J. C.; SILVA, H. J. N. da .; MELO, A. F. M. de .; BORGES, S. H. A. L.; SOUSA, A. C. M.; OLIVEIRA, J. C. de .; SANTANA, F. de S.; MARINHO, A. L. de S.; GUALBERTO , M. A. .; SOUSA , I. J. O.; GONÇALVES, R. L. G. .; SILVA, K. M. R. da .; PINHEIRO, I. M. Pharmacological treatment for endometriosis. Research, Society and Development, [S. l.], v. 10, n. 7, p. e52810716104, 2021. DOI: 10.33448/rsd-v10i7.16104. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/16104. Acesso em: 12 nov. 2024.

Issue

Section

Health Sciences